Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon Nov 25, 2020 12:04pm
137 Views
Post# 31970171

RE:RE:COVID serology test competitor approval

RE:RE:COVID serology test competitor approvalAny new tests coming out is a positive . This aprticular test is an ELISA  based test ... numerous tests with that  same science are on the market... ours will be different a different science , easier to administrate and way cheaper in price.. thats if our scientists in BC can make it perfect .. until they meet their expectations, they will not send it for approval.. right now its would be just another of 40-50 antibody tests  that aere going or on the market already ... an interesting thing I read yesterday but I could not copy the link,, a Moderna sceintist cautioned about the hype around the vaccine ...

1-  everyone is overlooking  a few things...  the vaccine(s)  are showing promise in being able to get the host to develop antibodies against covid -19 and that will hopefully protect the host  ( how long is still a question.) ..

2- but they have absolutley no idea if the vaccine will prevent the host from transmitting the virus  to others .. so I have this feeling that until  they have an idea that transmissions are also slowed down if you build the antibody immunity, the world is still going to be wearing masks, distancing and sanitizing surfaces...  or unitl we have over 75% of the population  vaccinated to create a herd immunity like we have with other vaccines and diseases. 
<< Previous
Bullboard Posts
Next >>